<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263260</url>
  </required_header>
  <id_info>
    <org_study_id>Inspiron RL II</org_study_id>
    <nct_id>NCT03263260</nct_id>
  </id_info>
  <brief_title>Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent</brief_title>
  <acronym>Inspiron RL II</acronym>
  <official_title>Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and
      efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of &quot;real-world&quot;
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0
      mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent.

      Stent implantation should be performed according to the Instructions for Use and according to
      the local practice. It is recommended that ECG and cardiac enzymes are collected before and
      after procedure. Dual anti-platelet therapy is recommended for at least 6 months after
      procedure.

      Patients will be followed at 30 days, 1 and 2 years after procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac Death, MI, Target Lesion Revascularization and Stent Thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Vessel and Lesion Revascularization Rates</measure>
    <time_frame>24 months</time_frame>
    <description>Target Vessel and Lesion Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Stent Thrombosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>implanted patients</arm_group_label>
    <description>Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>implant</intervention_name>
    <description>coronary stent implantation</description>
    <arm_group_label>implanted patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years submitted to implant of the Inspiron Sirolimus Eluting Stent
        in native coronary arteries
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  alll patients that have been treated with the Inspiron Sirolimus Eluting Stent older
             and 18 years

        Exclusion Criteria:

          -  Safein Vein or Left Internal Mammary artery Grafts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erico Rossi</last_name>
    <phone>+55 62 3625-5000</phone>
    <email>erossi@scitechmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>União Brasileira de Educação e Assistência - Hospital São Lucas da PUC - RS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90.619-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Caramori, Medicine</last_name>
      <email>caramori@cardiarte.com.br</email>
    </contact>
    <investigator>
      <last_name>Paulo Caramori, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent, DES, Inspiron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

